WO2025186634 - METHOD AND KIT FOR MONITORING ANTICOAGULANT THERAPY
National phase entry is expected:
Publication Number
WO/2025/186634
Publication Date
11.09.2025
International Application No.
PCT/IB2025/050980
International Filing Date
29.01.2025
Title **
[English]
METHOD AND KIT FOR MONITORING ANTICOAGULANT THERAPY
[French]
PROCÉDÉ ET KIT DE SUIVI D'UNE THÉRAPIE ANTICOAGULANTE
Applicants **
FIIX DIAGNOSTICS
Inventors
ONUNDARSON, Páll T.
GUDMUNDSDOTTIR, Brynja R.
Priority Data
63/560,939
04.03.2024
US
63/683,855
16.08.2024
US
18/823,356
03.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2279 | |
| EPO | Filing, Examination, Granting | 10681 | |
| Japan | Filing, Examination, Granting | 2309 | |
| South Korea | Filing, Examination, Granting | 2451 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
23,060
Contact Us
Abstract[English]
A method and kit are provided for monitoring anticoagulant therapy based on measuring the simultaneous influence of factors II and X only, in a test sample (i.e., test plasma or whole blood) of an anticoagulated patient, by creating a corrected sample that circumvents measuring also the influence of fibrinogen, factor V, and factor VII on the clotting process in the corrected sample. One or more coagulation reagents that activate factor VII or factor X, but not factor IX, are added to the corrected sample, and the blood clotting ability of the corrected plasma sample is subsequently determined by measuring blood clotting time. Alternatively, a reagent plasma with added factor VII is mixed into the reagent activator, such as thromboplastin, that is subsequently added to a sample of test plasma or whole blood to correct the test sample and measure the simultaneous influence of only factors II and X.[French]
L'invention concerne un procédé et un kit de suivi d'un traitement anticoagulant reposant sur la mesure de l'influence simultanée des facteurs II et X uniquement, dans un échantillon de test (c'est-à-dire du plasma de test ou du sang total) d'un patient sous anticoagulants, en créant un échantillon corrigé qui contourne la mesure de l'influence du fibrinogène, du facteur V et du facteur VII sur le processus de coagulation dans l'échantillon corrigé. Un ou plusieurs réactifs de coagulation qui activent le facteur VII ou le facteur X, mais pas le facteur IX, sont ajoutés à l'échantillon corrigé, et la capacité de coagulation sanguine de l'échantillon de plasma corrigé est ensuite déterminée par mesure du temps de coagulation sanguine. En variante, un plasma réactif à facteur VII ajouté est mélangé dans l'activateur de réactif, tel que la thromboplastine, qui est ensuite ajouté à un échantillon de plasma de test ou de sang total pour corriger l'échantillon de test et mesurer l'influence simultanée des seuls facteurs II et X.